Patent Registration-Marketing Linkage Row in India
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - With India's drug quality regulator announcing its intention to link giving marketing approval for a drug to its patent status, domestic pharmaceutical companies are up in arms against the move, while multinational firms have welcomed it
You may also be interested in...
Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals
With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies
Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals
With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies
Indian Court Restrains Cipla From Exporting Generic Tarceva
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said